-transparent.png){kind=logo}
The cell sensitivity of recombinant human alpha interferons (rIFN-alpha) of greater than 95% purity (A,D and the hybrid A/D) and crude nature (B and F) was studied in human (WISH, HeLa, AG1732), bovine (MDBK, BT), monkey (Vero), mouse (L), rabbit (RK-13), and hamster (BHK-21) cells. Based on an activity of 100% in WISH cells, the other cells responded to rIFN-alpha A as follows: AG1732 (90%), HeLa (94%), and MDBK and BT cells (170-190%). Rabbit, mouse, and hamster cells had a relative sensitivity of less than 1%. rIFN-alpha B and F were essentially equivalent to rIFN-alpha A in terms of cell sensitivity, but MDBK and BT cells were about 20 times more sensitive to rIFN-alpha D than were WISH cells and rIFN-alpha D was 1/5 to 1/10 as active on L cells as on WISH cells. The activity of the hybrid IFN A/D on bovine, mouse, and human cells was similar. The inhibitory dose50 (U/ml) of rIFN-alpha A, B, D, and F against virus infections in WISH cells were: vesicular stomatitis virus (1-4), rhinovirus types 1 and 42 (2-18), and herpes simplex virus (HSV) type 2 (45-70). Type 1 HSV, Semliki Forest (SFV) and encephalomyocarditis (EMC) viruses were tested against only rIFN-alpha A and D where SFV and EMC were the most sensitive to both IFNs (ID50-SFV, 0.2 U/ml, EMC, 1.2 U/ml) while 13 U/ml of rIFN-alpha A and D inhibited Type 1 HSV. The various rIFN-alpha s did not exhibit different antiviral spectra in vitro. When tested in mice rIFN-alpha A did not protect against infections with SFV, EMC, HSV, or influenza viruses. rIFN-alpha D and A/D protected mice infected with EMC, SFV, or HSV.
M J Kramer, and
R Dennin, and
C Kramer, and
G Jones, and
E Connell, and
N Rolon, and
A Gruarin, and
R Kale, and
P W Trown
February 1988,
Journal of interferon research,
M J Kramer, and
R Dennin, and
C Kramer, and
G Jones, and
E Connell, and
N Rolon, and
A Gruarin, and
R Kale, and
P W Trown
September 1986,
Virus research,
M J Kramer, and
R Dennin, and
C Kramer, and
G Jones, and
E Connell, and
N Rolon, and
A Gruarin, and
R Kale, and
P W Trown
January 1985,
Arzneimittel-Forschung,
M J Kramer, and
R Dennin, and
C Kramer, and
G Jones, and
E Connell, and
N Rolon, and
A Gruarin, and
R Kale, and
P W Trown
October 1986,
Journal of interferon research,
M J Kramer, and
R Dennin, and
C Kramer, and
G Jones, and
E Connell, and
N Rolon, and
A Gruarin, and
R Kale, and
P W Trown
November 1991,
Journal of virology,
M J Kramer, and
R Dennin, and
C Kramer, and
G Jones, and
E Connell, and
N Rolon, and
A Gruarin, and
R Kale, and
P W Trown
September 2003,
Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology,
M J Kramer, and
R Dennin, and
C Kramer, and
G Jones, and
E Connell, and
N Rolon, and
A Gruarin, and
R Kale, and
P W Trown
February 1990,
Biochemical and biophysical research communications,
M J Kramer, and
R Dennin, and
C Kramer, and
G Jones, and
E Connell, and
N Rolon, and
A Gruarin, and
R Kale, and
P W Trown
January 1987,
Iowa medicine : journal of the Iowa Medical Society,
M J Kramer, and
R Dennin, and
C Kramer, and
G Jones, and
E Connell, and
N Rolon, and
A Gruarin, and
R Kale, and
P W Trown
April 1987,
Journal of biological response modifiers,
M J Kramer, and
R Dennin, and
C Kramer, and
G Jones, and
E Connell, and
N Rolon, and
A Gruarin, and
R Kale, and
P W Trown
January 1987,
Differentiation; research in biological diversity,
